The global Head and Neck Cancer (HNC) Therapeutics market is expected to surpass an impressive valuation of USD 5.19 Billion in 2033 and is projected to exhibit a compound annual growth rate (CAGR) of 12.6% from 2023 to 2033.
Advances in the detection and treatment of head and neck cancer (HNC) are expected to drive market growth since they are less expensive and more precise to approach than surgeries. The increased incidences of multiple kinds of HNCs, as well as the rising geriatric population, are significant market drivers.
Head and neck cancers are categorized based on where they occur. These include the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity, and salivary glands. Increased alcohol and cigarette consumption is a major cause of head and neck cancer. Alcohol and cigarette use are thought to be responsible for 75% of head and neck cancers. Cancer will be the leading cause of death, accounting for over 10 million deaths, or one out of every six. As a consequence, this aspect is expected to propel market expansion.
Moreover, the United Nations estimates that there were approximately 727 million individuals aged 60 and over in the world by 2020. Aging deteriorates the immune system and makes individuals more susceptible to various types of HNCs, creating a market for therapeutic drugs for therapeutic strategies.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1.58 Billion |
| Anticipated Forecast Value (2033) | USD 5.19 Billion |
| Projected Growth Rate (2023 to 2033) | 12.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Patients with head and neck cancer are at significant risk of SARS-CoV-2 infection because they need prevalent outpatient services to evaluate disease processes and use systemic drug therapies to regulate deadly disease conditions. During the COVID-19 pandemic, the popularity of nonsurgical therapeutics such as chemotherapy, immunosuppression, and targeted therapy accelerated. Therefore, during the historical period the head and neck cancer (HNC) therapeutics market grew rapidly with a CAGR of 11.8%.
Furthermore, an increment in Research and Development activities involving the creation of novel therapeutic targets and multidisciplinary treatment approaches is anticipated to boost the survival rate of individuals with head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is presently in phase III clinical trials for therapies for squamous head and neck cancer. The FDA has designated it as a revolutionary therapy.
Presence of a comprehensive pipeline and the expected launch of these products benefit sales growth
The existence of a robust product pipeline and their anticipated launch will aid sales growth. Tipifarnib (Farnesyltransferase Inhibitor), tiragolumab (anti-TIGIT), Tecentriq (atezolizumab), Rozlytrek (entrectinib), and Afatinib are among the products in development. Over the forecast timeframe, market growth is expected to be stimulated by the satisfactory implementation of trials and subsequent approval. Tipifarnib, advanced by Kura Oncology, Inc., was designated as a revolutionary therapy by the US Food and Drug Administration in February 2021 for the treatment of individuals with head and neck squamous cell carcinoma (HNSCC). This is a powerful, specific, and orally administered medicine.
Rise in Prevalence of Cancer Patients to Push the Market Growth
As the number of individuals suffering from head and neck cancers continues to rise dramatically, there is an enormous spike in the demand for inventive cancer treatments all over the world. There has been a significant increase in the number of cases of head and neck cancer in recent years.
Based on a World Health Organization (WHO) report, more than 550,000 cases of head and neck cancer are observed each year, with approximately 300,000 deaths occurring as a result of these cancers. People are selecting treatments such as chemotherapy and radiotherapy to alleviate symptoms and boost their likelihood of surviving. Soaring cancer treatment adoption will continue to stimulate the expansion of the head and neck cancer (HNC) therapeutics market during the projected timeframe.
Principal Consultant
Chemotherapy-Related Side Effects to Limit Market Growth
Head and neck cancer is commonly treated with a combination of radiation and chemotherapy. Hair loss, speech difficulties, and diminished natural voice are among the side effects.
Furthermore, people who have had cancer surgery have trouble swallowing. Hair loss is a common side effect of chemotherapy, but it does not influence everybody. Individuals can inquire with their doctor if it is most likely a drug therapy side effect.
The high prevalence of head and neck cancer cases is predicted to expand North American Market
North America dominated the market, accounting for approximately 45% of total revenue in 2021. Government assistance for the advancement of the medical industry, favorable reimbursement policies, increased disease consciousness, increased Research and Development activities and effortless access to high-quality healthcare facilities are among the major factors influencing regional market expansion.
Based on the Cancer Research Institute, roughly 54,000 people were diagnosed with various types of HNC in 2021, with nearly 11,000 deaths reported throughout the United States. In the United States, head and neck cancer records about 4% of all cancers as per the report published by Cancer.net in 2022. As a result, the market in North America is expected to grow rapidly owing to the high prevalence of head and neck cancer cases.
Growing utilization of immunotherapeutic drugs drives the market growth
The market for head and neck cancer therapeutics is predicted to expand the fastest in the Asia Pacific over the projected timeframe. The burgeoning geriatric population, in addition to the increasing use of immunotherapeutic drugs such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo) for the treatment of various types of HNC, are expected to stimulate market growth in the future.
China is a major source of head and neck cancer, accounting for approximately 10% of all systemic malignant cancers each year. The survival rate of head and neck tumors is increasing as medical standards improve. After standardized treatment, the 5-year overall survival rate for head and neck tumors is around 80% in China. As a result, this factor is expected to contribute to the growth of the regional market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Novel immunotherapy drug approvals drive segment growth
The immunotherapy segment dominated the industry and accounted for 44% of total revenue in 2022. Based on the Cancer Research Institute, there are presently two approved PD-L1 inhibitors for the diagnosis of patients suffering from head and neck cancer: Nivolumab (Opdivo) and Pembrolizumab (Keytruda).
Dostarlimab (Jemperli) is being evaluated in Phase II clinical trials for the treatment of metastatic or reoccurring head and neck squamous cell carcinoma. As a result, the authorization of innovative immunotherapy drugs is anticipated to propel the growth of this segment.
Retail and specialty pharmacies accounted for the majority of profits
In 2022, the retail and specialty pharmacies segment ruled the market, accounting for 58% of total revenue. The supremacy can be credited to producers' choice for marketing their products owing to easy access to medications and minimal distribution expenses.
Humana specialty pharmacy, Accredo, CVS Specialty, and Optum specialty pharmacy have been the world's top five specialty pharmacies, based on the Drug Channels Institute's report 2021.
prominent start-up Players in the head and neck cancer (HNC) therapeutics market sector are introducing novel and innovative product lines to strengthen their market presence, and the aforementioned start-ups have left no stone unturned. The following are some specific examples of significant head and neck cancer (HNC) therapeutics market start-ups:
Key players in the head and neck cancer (HNC) therapeutics markets are Eli Lilly and Company, Sanofi, Merck & Co., Inc., Clinigen Group plc., Bristol-Myers Squibb Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd., Coherus BioSciences.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1.58 Billion |
| Anticipated Forecast Value (2033) | USD 5.19 Billion |
| Projected Growth Rate (2023 to 2033) | 12.6% CAGR |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Therapy Type, Route of Administration, Channel, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Eli Lilly and Company; Sanofi, Merck & Co., Inc.; Clinigen Group plc.; Bristol-Myers Squibb Company; AstraZeneca; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd; Hoffmann-La Roche Ltd.; Coherus BioSciences. |
| Customization | Available Upon Request |
The global market size to reach USD 5.19 billion by 2033.
The market is valued at USD 1.58 billion in 2023.
Eli Lilly and Company, Sanofi, Merck & Co., Inc., and Clinigen Group plc. are the key market players.
North America is likely to generate 45% revenue in 2021.
Immunotherapy is estimated to hold lucrative opportunities in the forecast period.
1. Executive Summary | Head and Neck Cancer (HNC) Therapeutics Market 2. Market Overview 3. Market Background 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 5.1. Chemotherapy 5.2. Immunotherapy 5.3. Targeted Therapy 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Injectable 6.2. Oral 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Channel 7.1. Retail & Specialty Pharmacies 7.2. Hospital Pharmacies 7.3. Online Pharmacies 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East & Africa (MEA) 9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Eli Lilly and Company 16.2. Sanofi 16.3. Merck & Co., Inc. 16.4. Clinigen Group plc. 16.5. Bristol-Myers Squibb Company 16.6. AstraZeneca 16.7. Takeda Pharmaceutical Company Limited 16.8. Teva Pharmaceutical Industries Ltd 16.9. F. Hoffmann-La Roche Ltd. 16.10. Coherus BioSciences 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Head and Neck Cancer (HNC) Therapeutics Market
